Results 241 to 250 of about 1,846,702 (390)

Dual‐Locking the SARS‐CoV‐2 Spike Trimer: An Amphipathic Molecular “Bolt” Stabilizes Conserved Druggable Interfaces for Coronavirus Inhibition

open access: yesAdvanced Science, EarlyView.
A new amphipathic molecule, S416 is discovered, that locks the SARS‐CoV‐2 spike protein in its closed state, blocking viral entry. S416 acts as a molecular bolt, binding six sites: three between adjacent RBDs and three connecting NTDs to RBDs. This dual‐locking mechanism stiffens the spike structure and reduces its flexibility.
Shiliang Li   +21 more
wiley   +1 more source

Performance evaluation of four kits for the detection of neutralizing antibody against SARS-CoV-2 in human serum

open access: yesJournal of Clinical Virology Plus
To evaluate four novel SARS-CoV-2 neutralizing antibody assay kits' application in neutralizing antibodies of population. Questionnaires from the voluntary participating researchers and selected the qualified questionnaires to analyse.
Hui Zhen   +9 more
doaj  

Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study. [PDF]

open access: yesSci Rep
Fraser DD   +12 more
europepmc   +1 more source

Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines

open access: yesAdvanced Science, EarlyView.
This review offers a comprehensive overview of pharmaceutical nanotechnology strategies to address limitations associated with the complex material basis and relative mild therapeutic efficacy of Chinese herbal medicines, and summarizes the advantages of these strategies.
Jiameng Li   +11 more
wiley   +1 more source

Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy. [PDF]

open access: yesInt J Mol Sci
Tsaregorodtseva TS   +8 more
europepmc   +1 more source

Tackling COVID-19 with neutralizing monoclonal antibodies

open access: yesCell, 2021
D. Corti   +3 more
semanticscholar   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy